[OTTAWA] June 3, 2021 – The BIOTECanada Board of Directors is pleased to announce the
election of Gordon C. McCauley, President and CEO AdMare BioInnovations, as Chair of
BIOTECanada at today’s Annual General Meeting. Mr. McCauley replaces Paul Petrelli,
President and General Manager Jazz Pharmaceuticals whose term as Chair has concluded.
Mr. Roberto Bellini, President & CEO, Bellus Health becomes Vice-Chair.
Following the Annual General Meeting of BIOTECanada, the BIOTECanada Board of Directors
is also announcing the election of four additional Directors to the Board.
The new Directors include:
- Andrew Haigh, President and CEO, Adapsyn Bioscience
- Frederic Ors, CEO, IMV Inc.
- Tracey Ramsay, Vice President and General Manager, AbbVie Canada
- Ali Tehrani, President and CEO, Zymeworks Inc.
“On behalf of the BIOTECanada team and the member companies, I extend appreciation to
the outgoing Directors for their time and commitment to the Association. I thank outgoing
Chair, Paul Petrelli for his outstanding leadership and counsel, especially during the
uncertainty of the COVID19 pandemic,” commented Andrew Casey President and CEO
BIOTECanada. “The Board also recognizes the commitment to the Association and the
industry of the Directors whose terms have been completed: Dan Wattier (ImStar
Therapeutics) who also served as Chair of the Emerging Companies Advisory Board, Chris
Aiello (Sanofi-Genzyme) and Jeffrey Miller (Alnylam Pharmaceuticals). Looking ahead, I very
much look forward to working with the entire Board in promoting policy initiatives to make
Canada’s biotechnology industry part of the economic recovery following COVID-19. Now is
the time for Canada to capitalize on its strong capacity in the life sciences to help effect
growth in our new economy.”
Hundreds of biotechnology companies are developing and introducing solutions to improve
agriculture and nutrition, protect our environment, and improve healthcare outcomes for
many other diseases. The sector is helping to fill the economic void of other industries
debilitated by the pandemic. As one of the country’s premiere high technology performers,
biotechnology continues to act as an innovation engine, a source of highly skilled
employment, and a destination for investment capital. It also creates innovative
technologies that lead to other industries, such as agriculture, resource management, and
manufacturing, being more competitive.
The 2021-2022 BIOTECanada Board of Directors
- Gordon C. McCauley, President and CEO AdMare BioInnovations (Chair)
- Roberto Bellini, President & CEO, Bellus Health (Vice Chair)
- Oliver Technow, CEO, BioVectra Inc. (Treasurer)
- Andrew Casey, President & CEO, BIOTECanada (Secretary)
- Norma Biln, CEO, Augurex
- Neal Carter, President & Founder, Okanagan Specialty Fruits
- Alok Kanti, General Manager, Bayer Canada
- Andrew Haigh, President and CEO, Adapsyn Bioscience
- Frederic Ors, CEO, IMV Inc.
- Melissa Koomey, Vice President & General Manager, Gilead Sciences Canada
- A.J. (Sandy) Marshall, Chairman, Bioindustrial Innovation Canada
- John Norman, Partner, Gowling WLG (Canada) LLP
- Tracey Ramsay, Vice President and General Manager, AbbVie Canada
- Alan Reba, General Manager, Bristol-Myers Squibb
- Sanj Singh, President & CEO, Temple Therapeutics B.V.
- Jamie Stiff, Managing Director, Genesys Capital
- Ali Tehrani, President and CEO, Zymeworks Inc.
- Shermaine Tilley, Managing Partner, CTI Life Sciences Fund
For more information
Nadine.Lunt@biotech.ca
613-793-6338